HomeMarketsSharesBioArctic AB ser. B

Trade BioArctic AB ser. B - BIOA B CFD

326.75+1.08%
The chart shows the BIOA B stock price data over the last 1 day, with a current price of 326.75, a high of 335.25, and a low of 323.65.
Low: 323.65High: 335.25
Sellers:
0%
Buyers:
100%
Past performance is not a reliable indicator of future results. Share prices are indicative and may differ from live market prices.
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread1.3
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
SEK 1,000.00
Overnight funding adjustment
Charges from full value of position
-0.015665 %
(-SEK 3.13)

Trade size with leverage ~ SEK 20,000.00

Money from leverage ~ $SEK 19,000.00


-0.01566%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
SEK 1,000.00
Overnight funding adjustment
Charges from full value of position
-0.006557 %
(-SEK 1.31)

Trade size with leverage ~ SEK 20,000.00

Money from leverage ~ $SEK 19,000.00


-0.00656%
Overnight funding adjustment time21:00 (UTC)
CurrencySEK
Min traded quantity1
Margin5.00%
Stock exchangeSweden
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close323.45
Open329.85
1-Year Change67.44%
Day's Range323.65 - 335.25

Trade BioArctic AB ser. B - BIOA B CFD

About BioArctic AB

BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, BioArctic AB revenues decreased 63% to SEK23.1M. Net loss applicable to common stockholders increased 75% to SEK119.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Labor & Related Expenses in SGA increase of 15% to SEK72.5M (expense).

Latest shares articles

Rheinmetall logo displayed on the exterior of a modern building.
Rheinmetall stock forecast: March guidance, cash flow concerns
Rheinmetall is a German defence group whose recent share price moves have reflected March 2026 guidance, broader tariff-driven market pressure, and continued focus on its expanding order backlog. Past performance is not a reliable indicator of future results. Explore third-party RHM price targets.
07:57, 30 April 2026
A smartphone displaying the Google logo in front of a screen showing the Alphabet company logo
Alphabet stock forecast: Q1 2026 earnings in focus
Alphabet is due to report Q1 2026 results after the US market close on 29 April, with investor attention on Google Cloud, Gemini AI, and its planned capital expenditure. Explore third-party GOOG price targets and technical analysis. Past performance is not a reliable indicator of future results.
07:40, 30 April 2026
Stellantis Stock Forecast | Q1 Results, Microsoft AI Pact
Stellantis stock forecast: Q1 results, Microsoft AI pact
Stellantis is a multinational carmaker due to report Q1 2026 results on 30 April, after announcing a five-year AI collaboration with Microsoft on 16 April 2026. Explore third-party STLAM price targets and technical analysis. Past performance is not a reliable indicator of future results.
09:39, 29 April 2026
Tesla logo displayed on a red storefront sign mounted on a building exterior
Tesla stock forecast: Q1 EPS beat, delivery miss
Tesla is an electric vehicle and energy company whose shares came under pressure after Q1 2026 earnings showed an EPS beat, weaker-than-expected deliveries and updates on FSD and Robotaxi plans. Explore third-party TSLA price targets. Past performance is not a reliable indicator of future results.
07:50, 29 April 2026
Related News
Public TechnologiesEurope
10:08 (UTC), 29 April 2026
Eisai says Leqembi annual sales top EUR 500 million in fiscal 2025
Public TechnologiesEurope
10:04 (UTC), 29 April 2026
BioArctic Q1 Leqembi royalties rise 68% to SEK 161 million
Public TechnologiesEurope
18:31 (UTC), 21 April 2026
BioArctic announces shareholder meeting
CisionEurope
18:30 (UTC), 21 April 2026
Notice of Annual General Meeting 2026 in BioArctic AB (publ)
Public TechnologiesEurope
18:00 (UTC), 21 April 2026
BioArctic publishes 2025 annual report and sustainability report

Read our reviews to find out more about us

Read the feedback from our clients, whatever their experience level.
2025-07-01
V***** F******* N***** S****

Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.

2025-06-30
B******

Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.

2025-06-27
G** G******

Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.

2025-06-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-06-19
d*********

I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️

2025-06-19
f*********

I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.

2025-05-29
C*********

Love the TV integration. Makes traders life smooth and comfortable.

2025-05-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-05-20
G****

I’d been paper trading for 2yrs now, went live and this platform is easy for beginners to understand and navigate all important tools to execute all that I learned. Earning now!

2025-04-29
d******

This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one

2025-02-06
N***** B***

User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.

2025-06-29
p*******

Capital is really great to be used on start, also beginner friendly broker! Great costumer support and it is quick!

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading